Observational studyNeurology(R) neuroimmunology & neuroinflammation2024
A Simple Score (MOG-AR) to Identify Individuals at High Risk of Relapse After MOGAD Attack.
Registry-linked trialAbstract readObservational Study
In one paragraph
Observational study in Neurology(R) neuroimmunology & neuroinflammation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05154370 (China National Registry of Neuro-Inflammatory Diseases), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
China National Registry of Neuro-Inflammatory Diseases: a Prospective Cohort Study
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Biomarkers to predict relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: a systematic review and meta-analysis.Journal of neurology, neurosurgery, and psychiatry · 2026Pooled it
- Clinical Prognostic Factors Associated With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Multicenter Cohort Study.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Identification of risk factors for relapse at initial onset in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis using ophthalmic findings.Japanese journal of ophthalmology · 2026Article
- Optimal strategies for treatment discontinuation in MOG antibody-associated disease.Brain : a journal of neurology · 2026Article
- Clinical risk factors for recurrence in adult-onset myelin oligodendrocyte glycoprotein antibody-associated optic neuritis.BMC ophthalmology · 2026Article
- Serum and CSF cytokine profile impact clinical phenotype in pediatric MOGAD.Journal of neuroinflammation · 2026Article
- Prediction of relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: external validation of the MOG-AR score.Journal of neurology · 2026Article
- Validation of the MOG-AR Score: A Retrospective Multicenter Study.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Clinical and laboratory findings in patients with anti-myelin oligodendrocyte glycoprotein antibodies: experience from two tertiary hospitals in Madrid.Frontiers in immunology · 2026Article
- Article
- Live Cell-Based Semi-Quantitative Stratification Highlights Titre-Dependent Phenotypic Heterogeneity in MOGAD: A Single-Centre Experience.International journal of molecular sciences · 2025Article
- MOGAD: A Shifting Landscape-From Pathogenesis to Personalised Management, Global Perspectives and Latin American Insights.Biomedicines · 2025Review
- The nomogram model predicts relapse risk in myelin oligodendrocyte glycoprotein antibody-associated disease: a single-center study.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Yun XuFrom the Department of Neurology (Y.X., L.Y., J.S., Y.Y., Y.W., H.C., H.W., T.S., F.-D.S., X.Z., D.-C.T.), China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University; Department of Neurology (H.M.), First Hospital of Shanxi Medical University, Taiyuan; Department of Neurology (M.F., C.-S.Y., F.-D.S.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (J.F.), The First Affiliated Hospital of Chongqing Medical University, China.
Huaxing MengFrom the Department of Neurology (Y.X., L.Y., J.S., Y.Y., Y.W., H.C., H.W., T.S., F.-D.S., X.Z., D.-C.T.), China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University; Department of Neurology (H.M.), First Hospital of Shanxi Medical University, Taiyuan; Department of Neurology (M.F., C.-S.Y., F.-D.S.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (J.F.), The First Affiliated Hospital of Chongqing Medical University, China.
Moli FanFrom the Department of Neurology (Y.X., L.Y., J.S., Y.Y., Y.W., H.C., H.W., T.S., F.-D.S., X.Z., D.-C.T.), China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University; Department of Neurology (H.M.), First Hospital of Shanxi Medical University, Taiyuan; Department of Neurology (M.F., C.-S.Y., F.-D.S.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (J.F.), The First Affiliated Hospital of Chongqing Medical University, China.
Linlin YinFrom the Department of Neurology (Y.X., L.Y., J.S., Y.Y., Y.W., H.C., H.W., T.S., F.-D.S., X.Z., D.-C.T.), China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University; Department of Neurology (H.M.), First Hospital of Shanxi Medical University, Taiyuan; Department of Neurology (M.F., C.-S.Y., F.-D.S.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (J.F.), The First Affiliated Hospital of Chongqing Medical University, China.
Jiali SunFrom the Department of Neurology (Y.X., L.Y., J.S., Y.Y., Y.W., H.C., H.W., T.S., F.-D.S., X.Z., D.-C.T.), China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University; Department of Neurology (H.M.), First Hospital of Shanxi Medical University, Taiyuan; Department of Neurology (M.F., C.-S.Y., F.-D.S.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (J.F.), The First Affiliated Hospital of Chongqing Medical University, China.
Yajun YaoFrom the Department of Neurology (Y.X., L.Y., J.S., Y.Y., Y.W., H.C., H.W., T.S., F.-D.S., X.Z., D.-C.T.), China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University; Department of Neurology (H.M.), First Hospital of Shanxi Medical University, Taiyuan; Department of Neurology (M.F., C.-S.Y., F.-D.S.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (J.F.), The First Affiliated Hospital of Chongqing Medical University, China.
Yuzhen WeiFrom the Department of Neurology (Y.X., L.Y., J.S., Y.Y., Y.W., H.C., H.W., T.S., F.-D.S., X.Z., D.-C.T.), China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University; Department of Neurology (H.M.), First Hospital of Shanxi Medical University, Taiyuan; Department of Neurology (M.F., C.-S.Y., F.-D.S.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (J.F.), The First Affiliated Hospital of Chongqing Medical University, China.
Hengri CongFrom the Department of Neurology (Y.X., L.Y., J.S., Y.Y., Y.W., H.C., H.W., T.S., F.-D.S., X.Z., D.-C.T.), China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University; Department of Neurology (H.M.), First Hospital of Shanxi Medical University, Taiyuan; Department of Neurology (M.F., C.-S.Y., F.-D.S.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (J.F.), The First Affiliated Hospital of Chongqing Medical University, China.
Huabing WangFrom the Department of Neurology (Y.X., L.Y., J.S., Y.Y., Y.W., H.C., H.W., T.S., F.-D.S., X.Z., D.-C.T.), China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University; Department of Neurology (H.M.), First Hospital of Shanxi Medical University, Taiyuan; Department of Neurology (M.F., C.-S.Y., F.-D.S.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (J.F.), The First Affiliated Hospital of Chongqing Medical University, China.
Tian SongFrom the Department of Neurology (Y.X., L.Y., J.S., Y.Y., Y.W., H.C., H.W., T.S., F.-D.S., X.Z., D.-C.T.), China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University; Department of Neurology (H.M.), First Hospital of Shanxi Medical University, Taiyuan; Department of Neurology (M.F., C.-S.Y., F.-D.S.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (J.F.), The First Affiliated Hospital of Chongqing Medical University, China.
Chun-Sheng YangFrom the Department of Neurology (Y.X., L.Y., J.S., Y.Y., Y.W., H.C., H.W., T.S., F.-D.S., X.Z., D.-C.T.), China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University; Department of Neurology (H.M.), First Hospital of Shanxi Medical University, Taiyuan; Department of Neurology (M.F., C.-S.Y., F.-D.S.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (J.F.), The First Affiliated Hospital of Chongqing Medical University, China.
Jinzhou FengFrom the Department of Neurology (Y.X., L.Y., J.S., Y.Y., Y.W., H.C., H.W., T.S., F.-D.S., X.Z., D.-C.T.), China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University; Department of Neurology (H.M.), First Hospital of Shanxi Medical University, Taiyuan; Department of Neurology (M.F., C.-S.Y., F.-D.S.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (J.F.), The First Affiliated Hospital of Chongqing Medical University, China.
Fu-Dong ShiFrom the Department of Neurology (Y.X., L.Y., J.S., Y.Y., Y.W., H.C., H.W., T.S., F.-D.S., X.Z., D.-C.T.), China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University; Department of Neurology (H.M.), First Hospital of Shanxi Medical University, Taiyuan; Department of Neurology (M.F., C.-S.Y., F.-D.S.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (J.F.), The First Affiliated Hospital of Chongqing Medical University, China.ORCID 0000-0002-9675-4637
Xinghu ZhangFrom the Department of Neurology (Y.X., L.Y., J.S., Y.Y., Y.W., H.C., H.W., T.S., F.-D.S., X.Z., D.-C.T.), China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University; Department of Neurology (H.M.), First Hospital of Shanxi Medical University, Taiyuan; Department of Neurology (M.F., C.-S.Y., F.-D.S.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (J.F.), The First Affiliated Hospital of Chongqing Medical University, China.
De-Cai TianFrom the Department of Neurology (Y.X., L.Y., J.S., Y.Y., Y.W., H.C., H.W., T.S., F.-D.S., X.Z., D.-C.T.), China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University; Department of Neurology (H.M.), First Hospital of Shanxi Medical University, Taiyuan; Department of Neurology (M.F., C.-S.Y., F.-D.S.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (J.F.), The First Affiliated Hospital of Chongqing Medical University, China.ORCID 0000-0002-5153-2491
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesTo identify predictors for relapse in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and to develop and validate a simple risk score for predicting relapse.
methodsIn China National Registry of Neuro-Inflammatory Diseases (CNRID), we identified patients with MOGAD from March 2023 and followed up prospectively to September 2023. The primary endpoint was MOGAD relapse, confirmed by an independent panel. Patients were randomly divided into model development (75%) and internal validation (25%) cohorts. Prediction models were constructed and internally validated using Andersen-Gill models. Nomogram and relapse risk score were generated based on the final prediction models.
resultsA total of 188 patients (comprising 612 treatment episodes) were included in cohorts. Female (HR: 0.687, 95% CI 0.524-0.899, DISCUSSION: The risk of MOGAD relapse seems to be predictable. Further validation of MOG-AR score developed from this cohort to determine appropriate treatment and monitoring frequency is warranted. TRIAL REGISTRATION INFORMATION: CNRID, NCT05154370, registered December 13, 2021, first enrolled December 15, 2021.
Indexed as
Myelin-Oligodendrocyte GlycoproteinRecurrenceRegistriesAdolescentAdultAutoantibodiesChinaDemyelinating Autoimmune Diseases, CNSFemaleFollow-Up StudiesHumansMaleMiddle AgedRisk AssessmentRisk FactorsYoung AdultAutoantibodiesMOG protein, humanMyelin-Oligodendrocyte Glycoprotein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT05154370ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.